

---

## ESOCAP ANNOUNCES THE SUCCESSFUL CLOSING OF ITS PRIVATE PLACEMENT OFFERING

*Basel, Switzerland, July 13th, 2018*

**EsoCap AG announced that it has successfully completed a private placement financing round on July 13<sup>th</sup>, 2018. The proceeds of the capital increase will be used toward the completion of the technical development of EsoCap's unique drug delivery technology and the initiation of a clinical proof-of-concept trial in eosinophilic esophagitis (EoE).**

"We are delighted to have secured the financial resources to continue our fast paced development program," said Isabelle Racamier, CEO of EsoCap. "This financing allows EsoCap to finalize the technical development of its unique topical drug delivery platform for diseases of the upper gastrointestinal tract. The company is now in a position to rapidly advance its innovative technology toward the clinic."

The private financing round includes investments from existing as well as from new investors with a strong entrepreneurial and scientific background. This funding is instrumental as it provides a solid bridge to clinical development.

### Contact:

Isabelle Racamier, CEO  
EsoCap AG  
Malzgasse 9  
4052 Basel  
Switzerland

[isabelle.racamier@esocapbiotech.com](mailto:isabelle.racamier@esocapbiotech.com)



EsoCap

### About EsoCap AG

EsoCap is a Swiss privately funded company based in Basel, Switzerland.

EsoCap's vision is to improve the lives of patients with serious diseases of the upper gastrointestinal tract through the development of a unique topical drug delivery platform.

Topical treatment in the upper gastrointestinal tract is extremely difficult to achieve due to ultra-short transit times with less than two seconds from the mouth to the stomach.

EsoCap owns a unique drug delivery platform allowing the topical application of drug substances for the local treatment of diseases of the upper gastrointestinal tract.

For more information, please visit [www.esocapbiotech.com](http://www.esocapbiotech.com).